Article
Cardiac & Cardiovascular Systems
Lorenzo Da Dalt, Laura Castiglioni, Andrea Baragetti, Matteo Audano, Monika Svecla, Fabrizia Bonacina, Silvia Pedretti, Patrizia Uboldi, Patrizia Benzoni, Federica Giannetti, Andrea Barbuti, Fabio Pellegatta, Serena Indino, Elena Donetti, Luigi Sironi, Nico Mitro, Alberico Luigi Catapano, Giuseppe Danilo Norata
Summary: PCSK9 deficiency impacts cardiac lipid metabolism and development of heart failure with preserved ejection fraction (HFpEF) independently of LDLR.
EUROPEAN HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Lorenzo Da Dalt, Laura Castiglioni, Andrea Baragetti, Matteo Audano, Monika Svecla, Fabrizia Bonacina, Silvia Pedretti, Patrizia Uboldi, Patrizia Benzoni, Federica Giannetti, Andrea Barbuti, Fabio Pellegatta, Serena Indino, Elena Donetti, Luigi Sironi, Nico Mitro, Alberico Luigi Catapano, Giuseppe Danilo Norata
Summary: The study showed that PCSK9 deficiency impacts cardiac lipid metabolism independently of LDLR and contributes to the development of heart failure with preserved ejection fraction (HFpEF).
EUROPEAN HEART JOURNAL
(2021)
Review
Cardiac & Cardiovascular Systems
Chayakrit Krittanawong, Muzamil Khawaja, Robert S. Rosenson, Christopher Amos, Vijay Nambi, Carl J. Lavie, Salim S. Virani
Summary: Genetic polymorphisms can cause variations in drug-gene response. Investigating these polymorphisms can help identify novel mechanisms related to specific diseases. Mendelian randomization uses genetic variants as instrumental variables to analyze the effects of modifiable risk factors. In the past decade, advances in understanding genetic polymorphisms have led to the identification of candidate genes that affect cholesterol regulation and cardiovascular disease outcomes. Personalized medicine considers genetic variations and targets different patient populations for drug use.
CURRENT PROBLEMS IN CARDIOLOGY
(2022)
Review
Pharmacology & Pharmacy
Sandra Hummelgaard, Joachim Pold Vilstrup, Camilla Gustafsen, Simon Glerup, Kathrin Weyer
Summary: Lowering blood cholesterol levels is crucial for reducing the risk of ASCVD, and PCSK9 plays a key role in cholesterol metabolism. Inhibiting PCSK9 has been shown to effectively reduce cholesterol levels and mitigate the risk of ASCVD events.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Medicine, Research & Experimental
Qian Xu, Yi-meng Zhao, Nai-qi He, Rong Gao, Wen-xin Xu, Xiu-juan Zhuo, Zhong Ren, Chun-yan Wu, Lu-shan Liu
Summary: Heart failure is a complex clinical syndrome caused by various cardiovascular diseases, with pathogenesis involving cardiomyocyte loss, myocardial energy metabolism disorder, and activation of cardiac inflammation. The increased level of PCSK9 in heart failure patients suggests a potential involvement of PCSK9 in the disease, although the specific mechanism is yet to be explored.
BIOMEDICINE & PHARMACOTHERAPY
(2023)
Review
Endocrinology & Metabolism
Connie B. Newman, Jonathan A. Tobert
Summary: The discovery of PCSK9 as a therapeutic target for reducing LDL cholesterol has led to the development of monoclonal antibodies and gene silencing methods that effectively lower cholesterol levels. However, the use of these treatments in clinical practice is hindered by economic considerations.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Cardiac & Cardiovascular Systems
Csaba Matyas, Eszter Trojnar, Suxian Zhao, Muhammad Arif, Partha Mukhopadhyay, Attila Kovacs, Alexandra Fabian, Marton Tokodi, Zsolt Bagyura, Bela Merkely, Laszlo Kohidai, Eszter Lajko, Angela Takacs, Yong He, Bin Gao, Janos Paloczi, Falk W. Lohoff, Gyorgy Hasko, Wen-Xing Ding, Pal Pacher
Summary: This study found a positive correlation between PCSK9 and age-related CVD, and demonstrated that PCSK9 inhibition can effectively slow down the progression of CVD in aging rats.
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2023)
Review
Cardiac & Cardiovascular Systems
Pinchao Lv, Yuxi Li, Lin Wu, Haoyu Weng, Ming Chen, Wenhui Ding, Jianping Li
Summary: PCSK9i, a novel lipid-lowering drug, has been used in patients after heart transplantation but less common in cases after kidney transplantation. This case report highlights the significant lipid-lowering efficacy and absence of significant adverse effects in a renal transplant recipient with hepatitis B treated with PCSK9i.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Cardiac & Cardiovascular Systems
Amedeo Tirandi, Fabrizio Montecucco, Luca Liberale
Summary: The amount of physical activity practiced by people has been decreasing in recent decades, leading to higher risks of atherosclerosis and related cardiovascular events. Regular physical activity has beneficial effects on metabolism and can help prevent cardiovascular diseases. Several studies have found lower levels of plasma lipids in individuals who engage in exercise, but the exact mechanisms by which physical activity modulates lipoproteins are still not fully understood.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Toshiyuki Nishikido, Kausik K. Ray
Summary: LDL cholesterol plays a key role in atherosclerosis progression, and statin therapy is recommended for reducing LDL-C levels and cardiovascular disease risk. For patients unable to achieve sufficient LDL-C reduction with statins or are statin-intolerant, PCSK9 inhibitors are an alternative treatment that significantly reduces LDL-C levels and cardiovascular risk.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Mario Luca Morieri, Valentina Perrone, Chiara Veronesi, Luca Degli Esposti, Margherita Andretta, Mario Plebani, Gian Paolo Fadini, Saula Vigili de Kreutzenberg, Angelo Avogaro
Summary: This study identified factors contributing to low achievement of LDL-cholesterol targets and underuse of lipid-lowering treatments in high- or very-high-cardiovascular risk patients. Gender, age, HDL-c, and triglyceride levels were found to delay statin prescriptions, indicating a need for modification to improve cardiovascular disease prevention. Late initiation of high-intensity treatments, especially in perceived low-risk patients, was highlighted as a key factor that needs to be addressed.
CARDIOVASCULAR DIABETOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Lina S. Silva-Bermudez, Andrea Vargas-Villanueva, Carlos A. Sanchez-Vallejo, Ana C. Palacio, Andres F. Buitrago, Carlos O. Mendivil
Summary: This study found that high plasma levels of hsCRP and PCSK9 were associated with early decreases in LVEF after an MI in South American patients.
LIPIDS IN HEALTH AND DISEASE
(2022)
Article
Cardiac & Cardiovascular Systems
Alvaro Acena, Juan Antonio Franco Pelaez, Ana Maria Pello Lazaro, Emilio Gonzalez Parra, Oscar Gonzalez Lorenzo, Juan Martinez-Mina, Ignacio Hernandez, Maria Luisa Martin-Mariscal, Marta Lopez Castillo, Andrea Kallmeyer, Oscar Lorenzo, Maria Luisa Gonzalez-Casaus, Jesus Egido, Jose Tunon
Summary: A study of 283 patients with ACS found that PCSK9 plasma levels, HS-CRP levels, dyslipidemia, history of PAD, and GFR are independent predicting factors of ASP progression. Low plasma levels of PCSK9 and elevated levels of HS-CRP are identified as independent predictors of ASP in patients with ischemic heart disease.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
(2021)
Review
Cardiac & Cardiovascular Systems
Yusuf Ziya Sener, Lale Tokgozoglu
Summary: This review summarizes the effects of PCSK9 in tissues other than the liver and highlights its crucial roles in the heart, brain, and kidney. Targeting PCSK9 for the treatment of hypercholesterolemia is effective in preventing cardiovascular diseases, making it important to understand its effects in other tissues.
CURRENT CARDIOLOGY REPORTS
(2023)
Article
Cardiac & Cardiovascular Systems
Arjen J. Cupido, Laurens F. Reeskamp, Aroon D. Hingorani, Chris Finan, Folkert W. Asselbergs, G. Kees Hovingh, Amand F. Schmidt
Summary: This study explored the associations of combined reduction of CETP and PCSK9 concentrations with risk of coronary artery disease and other clinical and safety outcomes. The results suggest that joint inhibition of CETP and PCSK9 has additive effects on lipid traits and disease risk, including a lower risk of CAD.
Review
Pathology
Valentin Blanchard, Ilya Khantalin, Stephane Ramin-Mangata, Kevin Chemello, Brice Nativel, Gilles Lambert
Editorial Material
Cardiac & Cardiovascular Systems
Kevin Chemello, Cesar Martin, Gilles Lambert
Article
Urology & Nephrology
Michele Chabert, Xavier Rousset, Magali Colombat, Michel Lacasa, Hermine Kakanakou, Mathilde Bourderioux, Pierre Brousset, Odile Burlet-Schiltz, Juris J. Liepnieks, Barbara Kluve-Beckerman, Gilles Lambert, Francois P. Chatelet, Merrill D. Benson, Athina D. Kalopissis
KIDNEY INTERNATIONAL
(2019)
Article
Hematology
Mikael Croyal, Valentin Blanchard, Khadija Ouguerram, Maud Chetiveaux, Lea Cabioch, Thomas Moyon, Stephanie Billon-Crossouard, Audrey Aguesse, Karine Bernardeau, Cedric Le May, Laurent Flet, Gilles Lambert, Samy Hadjadj, Bertrand Cariou, Michel Krempf, Estelle Nobecourt-Dupuy
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Benny J. Evison, James T. Palmer, Gilles Lambert, Herbert Treutlein, Jun Zeng, Brice Nativel, Kevin Chemello, Qing Zhu, Jie Wang, Yanfen Teng, Wei Tang, Yanfeng Xu, Anuj Kumar Rathi, Sanjay Kumar, Alexandra K. Suchowerska, Jasneet Parmar, Ian Dixon, Graham E. Kelly, James Bonnar
BIOORGANIC & MEDICINAL CHEMISTRY
(2020)
Letter
Clinical Neurology
Brice Nativel, Stephane Ramin-Mangata, David Couret, Cynthia Planesse, Mathias Roche, Antonio Gallo, Olivier Meilhac, Gilles Lambert, Steeve Bourane
Article
Biochemistry & Molecular Biology
Kepa B. Uribe, Kevin Chemello, Asier Larrea-Sebal, Asier Benito-Vicente, Unai Galicia-Garcia, Steeve Bourane, Ali K. Jaafar, Gilles Lambert, Cesar Martin
Summary: Research shows that GOF mutations of the PCS9 gene lead to familial hypercholesterolemia, while LOF mutations are associated with reduced cholesterol levels. By studying the effects of different PCS9 variants on LDLR expression and affinity through transient transfections of HEK293 and HepG2 cells, it is possible to reliably determine their GOF or LOF status.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Peripheral Vascular Disease
Kevin Chemello, Dirk J. Blom, A. David Marais, Gilles Lambert, Valentin Blanchard
Summary: Lp(a) is a highly atherogenic lipoprotein species with strong genetic determination of its concentration. The APOE gene, in addition to the LPA gene, plays an important role in modulating Lp(a) concentrations. Carriers of the APOE2 variant display lower Lp(a) levels, but this does not significantly affect circulating Lp(a). Mechanistically, apoE appears to affect the production, but not the catabolism, of Lp(a).
CURRENT ATHEROSCLEROSIS REPORTS
(2022)
Article
Cardiac & Cardiovascular Systems
Florian Kronenberg, Samia Mora, Erik S. G. Stroes, Brian A. Ference, Benoit J. Arsenault, Lars Berglund, Marc R. Dweck, Marlys Koschinsky, Gilles Lambert, Francois Mach, Catherine J. McNeal, Patrick M. Moriarty, Pradeep Natarajan, Borge G. Nordestgaard, Klaus G. Parhofer, Salim S. Virani, Arnold von Eckardstein, Gerald F. Watts, Jane K. Stock, Kausik K. Ray, Lale S. Tokgozoglu, Alberico L. Catapano
Summary: This consensus statement provides updated evidence on the role of Lp(a) in ASCVD and aortic valve stenosis, and offers clinical guidance on testing and treating elevated Lp(a) levels.
EUROPEAN HEART JOURNAL
(2022)
Article
Biochemistry & Molecular Biology
Alexandra K. Suchowerska, Geurt Stokman, James T. Palmer, Phillip A. Coghlan, Elsbet J. Pieterman, Nanda Keijzer, Gilles Lambert, Kevin Chemello, Ali K. Jaafar, Jasneet Parmar, Liping Yan, Yingtao Tong, Lin Mu, Hans M. G. Princen, James Bonnar, Benny J. Evison
Summary: This study reported the discovery of an orally bioavailable small-molecule inhibitor of PCSK9 called NYX-PCSK9i, which demonstrated significant cholesterol-lowering activity in hyperlipidemic APOE*3-Leiden.CETP mice. NYX-PCSK9i has the potential to be a new therapy for hypercholesterolemia and can enhance the lipid-lowering activities of statins.
JOURNAL OF LIPID RESEARCH
(2022)
Review
Biochemistry & Molecular Biology
Ali K. Jaafar, Romuald Techer, Kevin Chemello, Gilles Lambert, Steeve Bourane
Summary: This article comprehensively reviews the role of PCSK9 in lipid metabolism and cardiovascular health, as well as its potential roles in the central and peripheral nervous systems. It focuses particularly on its involvement in cerebrovascular and neurodegenerative diseases.
JOURNAL OF LIPID RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Kevin Chemello, Sandra Beeske, Thi Thu Trang Tran, Valentin Blanchard, Elise F. Villard, Bruno Poirier, Jean-Christophe Le Bail, Gihad Dargazanli, Sophie Ho-Van-Guimbal, Denis Boulay, Olivier Bergis, Marie-Pierre Pruniaux, Mikael Croyal, Philip Janiak, Etienne Guillot, Gilles Lambert
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2020)
Letter
Cardiac & Cardiovascular Systems
Valentin Blanchard, Mikael Croyal, Ilya Khantalin, Stephane Ramin-Mangata, Kevin Chemello, Brice Nativel, Dirk. J. Blom, A. David Marais, Gilles Lambert
JACC-BASIC TO TRANSLATIONAL SCIENCE
(2019)
Article
Cardiac & Cardiovascular Systems
Ilya Khantalin, Valentin Blanchard, Nicolas Viallet, Gilles Lambert
EUROPEAN HEART JOURNAL-CASE REPORTS
(2019)
